Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CCR1 | P32246 | 4/20 | 0.40 |
| ▸ | CCR8 | P51685 | 4/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101525 | 0.82 | ALDH1A1 (0.40) | ALDH1A1CCR1CCR8CCR5HTT | |
| SCHEMBL28846255 | 0.77 | CCR1 (0.43) | ALDH1A1CCR1CCR8CCR5SMN1; SMN2 | |
| SCHEMBL2624387 | 0.76 | CCR1 (0.37) | ALDH1A1CCR1CCR8CCR5PSMD14 | |
| SCHEMBL16901678 | 0.75 | ALDH1A1 (0.42) | ALDH1A1CCR1CCR8CCR5HTT | |
| SCHEMBL15966361 | 0.75 | HTT (0.42) | ALDH1A1CCR1CCR8CCR5HTT | |
| SCHEMBL18660657 | 0.75 | HTT (0.38) | ALDH1A1CCR1CCR8CCR5PSMD14 | |
| SCHEMBL9277705 | 0.75 | SGMS2 (0.36) | ALDH1A1CCR1CCR8CCR5PSMD14 | |
| SCHEMBL15935208 | 0.75 | ALDH1A1 (0.35) | ALDH1A1CCR1CCR8CCR5PSMD14 | |
| SCHEMBL10507830 | 0.73 | KDM4E (0.49) | ALDH1A1CCR1CCR8HTTSMN1; SMN2 | |
| SCHEMBL26102666 | 0.73 | MAOA (0.47) | ALDH1A1CCR1CCR8CCR5PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20070265299-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-4577014-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4501739-A | BACTERICIDES, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | ALDH1A1 2888/4885CCR1 2659/4885CCR8 4115/4885 |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | ALDH1A1 2167/4885CCR1 4495/4885CCR8 3902/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | ALDH1A1 2167/4885CCR1 4495/4885CCR8 3902/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | ALDH1A1 844/4885CCR1 4743/4885CCR8 4663/4885 |
| US-20070265299-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | ALDH1A1 1372/4885CCR1 500/4885CCR8 697/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | ALDH1A1 1903/4885CCR1 4869/4885CCR8 4835/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | ALDH1A1 1331/4885CCR1 4847/4885CCR8 4806/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | ALDH1A1 3748/4885CCR1 1697/4885CCR8 3728/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | ALDH1A1 1494/4885CCR1 464/4885CCR8 432/4885 |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | YEATS2, YEATS4, KNTC1 | ALDH1A1 3939/4885CCR1 3976/4885CCR8 4522/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | ALDH1A1 1331/4885CCR1 4847/4885CCR8 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.